{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:23:54Z","timestamp":1783513434870,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:00:00Z","timestamp":1504310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12032-017-1033-z","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T07:12:12Z","timestamp":1504336332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette\u2013Gu\u00e9rin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"34","author":[{"given":"Esmee I. M. L.","family":"Liem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Baard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne C. C.","family":"Cauberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke T. J.","family":"Bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Martijn","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Pilar","family":"Laguna Pes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean J. M. C. H.","family":"de la Rosette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,2]]},"reference":[{"issue":"3","key":"1033_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447\u2013461. doi:\n                    10.1016\/j.eururo.2016.05.041\n                    \n                  .","journal-title":"Eur Urol"},{"key":"1033_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol (Elsevier Ltd). 2016;196:1021\u20139.","journal-title":"J Urol (Elsevier Ltd)"},{"key":"1033_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce A. Intracavitary Bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180\u20133.","journal-title":"J Urol"},{"key":"1033_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, Van De Beek C, Van Andel G, et al. Side effects of Bacillus Calmette\u2013Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69\u201376.","journal-title":"Eur Urol"},{"key":"1033_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"APM Meijden Van der","year":"2003","unstructured":"Van der Meijden APM, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette\u2013Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial. Eur Urol. 2003;44:429\u201334.","journal-title":"Eur Urol"},{"key":"1033_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","volume":"59","author":"V Pansadoro","year":"2002","unstructured":"Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette\u2013Gu\u00e9rin: 18-year experience. Urology. 2002;59:227\u201331.","journal-title":"Urology"},{"key":"1033_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR. Intravesical Bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90\u20135.","journal-title":"J Urol"},{"key":"1033_CR8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"KG Nepple","year":"2010","unstructured":"Nepple KG, Lightfoot AJ, Rosevear HM, O\u2019Donnell MA, Lamm DL. Bacillus Calmette\u2013Gu\u00e9rin with or without interferon a-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184:1915\u20139.","journal-title":"J Urol"},{"key":"1033_CR9","doi-asserted-by":"publisher","first-page":"108.e1","DOI":"10.1016\/j.urolonc.2014.02.020","volume":"33","author":"HW Herr","year":"2015","unstructured":"Herr HW, Milan TN, Dalbagni G. BCG-refractory versus BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol (Elsevier). 2015;33:108.e1\u20134.","journal-title":"Urol Oncol (Elsevier)"},{"key":"1033_CR10","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, Bohle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34:1935\u201344.","journal-title":"J Clin Oncol"},{"key":"1033_CR11","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","volume":"164","author":"KC Halling","year":"2000","unstructured":"Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768\u201375.","journal-title":"J Urol"},{"key":"1033_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0022-5347(01)64079-5","volume":"159","author":"A Pycha","year":"1998","unstructured":"Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H, Marberger M. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol. 1998;159:265\u20139.","journal-title":"J Urol"},{"key":"1033_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1309\/K5P2-4Y8B-7L5A-FAA9","volume":"116","author":"L Bubendorf","year":"2001","unstructured":"Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79\u201386.","journal-title":"Am J Clin Pathol"},{"key":"1033_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/01.ju.0000149825.83180.a4","volume":"173","author":"BR Kipp","year":"2005","unstructured":"Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005;173:401\u20134.","journal-title":"J Urol"},{"key":"1033_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1464-410X.2009.08375.x","volume":"104","author":"J Whitson","year":"2009","unstructured":"Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int. 2009;104:336\u20139.","journal-title":"BJU Int"},{"key":"1033_CR16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.eururo.2007.03.001","volume":"52","author":"L Mengual","year":"2007","unstructured":"Mengual L, Marin-Aguilera M, Ribal MJ, Burset B, Villavicencio H, Oliver A, et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with Bacillus Calmette\u2013Guerin therapy. Eur Urol. 2007;52:752\u20139.","journal-title":"Eur Urol"},{"key":"1033_CR17","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1002\/ijc.24258","volume":"124","author":"S Savic","year":"2009","unstructured":"Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette\u2013Gu\u00e9rin therapy. Int J Cancer. 2009;124:2899\u2013904.","journal-title":"Int J Cancer"},{"key":"1033_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","volume":"187","author":"AM Kamat","year":"2012","unstructured":"Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, et al. Use of fluorescence in situ hybridization to predict response to Bacillus Calmette\u2013Guerin therapy for bladder cancer: results of a prospective trial. J Urol. 2012;187:862\u20137.","journal-title":"J Urol"},{"key":"1033_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","volume":"112","author":"NM Gandhi","year":"2013","unstructured":"Gandhi NM, Morales A, Lamm DL. Bacillus Calmette\u2013Gu\u00e9rin immunotherapy for genitourinary cancer. BJU Int. 2013;112:288\u201397.","journal-title":"BJU Int"},{"key":"1033_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-5347(01)62065-2","volume":"161","author":"TM Reijke de","year":"1999","unstructured":"de Reijke TM, Boer ECDE, Kurth KH, Schamhart DHJ. Urinary interleukin-2 monitoring during prolonged Bacillus Calmette\u2013Guerin treatment: Can it predict the optimal number of instillations? J Urol. 1999;161:67\u201371.","journal-title":"J Urol"},{"key":"1033_CR21","first-page":"1341","volume":"146","author":"C Voorter","year":"1995","unstructured":"Voorter C, Joos S, Bringuier PP, Vallinga M, Poddighe P, Schalken J, et al. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol. 1995;146:1341\u201354.","journal-title":"Am J Pathol"},{"key":"1033_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/(SICI)1096-9896(199808)185:4<345::AID-PATH109>3.0.CO;2-0","volume":"185","author":"R Simon","year":"1998","unstructured":"Simon R, B\u00fcrger H, Brinkschmidt C, B\u00f6cker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J. Pathol. 1998;185:345\u201351.","journal-title":"J. Pathol."},{"key":"1033_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/labinvest.3700068","volume":"84","author":"R Stoehr","year":"2004","unstructured":"Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab. Investig. 2004;84:465\u201378.","journal-title":"Lab. Investig."},{"key":"1033_CR24","first-page":"409","volume":"28","author":"PJ Goebell","year":"2010","unstructured":"Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol Semin Orig Investig (Elsevier Inc). 2010;28:409\u201328.","journal-title":"Urol Oncol Semin Orig Investig (Elsevier Inc)"},{"key":"1033_CR25","first-page":"315","volume":"507","author":"T Cancer","year":"2014","unstructured":"Cancer T, Atlas G, Weinstein JN, Akbani R, Broom BM, Wang W, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (Nature Publishing Group). 2014;507:315\u201322.","journal-title":"Nature (Nature Publishing Group)"},{"key":"1033_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, Van De Beek C, Van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus calmette-gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1\u00a0year versus 3\u00a0years of maintenance. Eur Urol. 2013;63:462\u201372.","journal-title":"Eur Urol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1033-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T17:42:46Z","timestamp":1552671766000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1033-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,2]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1033-z","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,2]]},"assertion":[{"value":"4 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance of ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The medical ethical committee of the Academic Medical Center reviewed the study protocol and concluded that the study did not imply that participants of the study were subjected to procedures or were required to follow rules of behavior according the \u2018Wet Medisch-wetenschappelijk onderzoek met mensen\u2019 (WMO). The WMO is the Medical Research involving Human Beings Act. When the research does not fall under the scope of the WMO, then the protocol does not have to be reviewed by an accredited medical research ethical committee. Therefore, approval of the medical ethical committee was not required. A copy of this decision is available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was verbally obtained from all participants prior to inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"172"}}